Safety and efficacy of defibrotide for the treatment of severe hepatic veno-occlusive disease by Richardson, Paul M. et al.
Ther Adv Hematol
(2012) 3(4) 253 –265
DOI: 10.1177/ 
2040620712441943
© The Author(s), 2012.  
Reprints and permissions:  
http://www.sagepub.co.uk/ 
journalsPermissions.nav
Therapeutic Advances in Hematology Review 
http://tah.sagepub.com 253
Introduction
Hepatic veno-occlusive disease (VOD) is a seri-
ous condition that usually arises within the first 
30 days after hematopoietic stem-cell transplanta-
tion (SCT), and is believed to be the result of 
endothelial cell damage and hepatocellular injury 
from high-dose conditioning regimens prior to 
SCT [Bearman, 1995; Kumar et al. 2003]. VOD 
is characterized by rapid weight gain, painful 
hepatomegaly, hyperbilirubinemia/jaundice, and 
ascites/fluid retention, without other identifiable 
causes for liver disease; VOD is fatal in 20–50% of 
patients [Bearman, 1995; Kumar et al. 2003]. 
Clinical criteria for the diagnosis of VOD have 
been developed; Seattle criteria stipulate that at 
least two or more clinical features including jaun-
dice, painful hepatomegaly or ascites, and/or 
unexplained weight gain must be evident within 
30 days of transplantation [Bearman, 1995; 
McDonald et al. 1984]; Baltimore criteria specify 
an elevated bilirubin level of at least 2.0 mg/dl 
and two or more of the following characteristics: 
hepatomegaly, ascites, or at least 5% weight gain 
by day 21 post-SCT [Bearman, 1995; Jones et al. 
1987]. Although not included in the formal 
diagnostic criteria in the past, it has also been 
found that rapid and unexpected elevations in 
the blood levels of specific anti-graft-versus- 
host-disease (GvHD) drugs (such as sirolimus 
and tacrolimus) in association with a rise in cre-
atinine as well as fluid avidity and weight gain 
(but prior to liver function abnormalities emerging) 
can be a valuable hint that VOD and sinusoidal 
obstruction may be evolving [Cutler et al. 2010].
In this article, we review the incidence and patho-
genesis of VOD, and evaluate approaches to the 
treatment of the disease. In particular, we focus 
on the safety and efficacy of the investigational 
drug, defibrotide, a polydisperse mixture of por-
cine-derived single-stranded oligonucleotides 
[Bianchi et al. 1993], and its potential for the 
treatment and prophylaxis of VOD in patients 
undergoing SCT.
Prevalence of veno-occlusive disease
A recent analysis of retrospective data, prospec-
tive cohort studies and clinical trials published 
between 1979 and 2007 detailed the prevalence 
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and severity of VOD [Coppell et al. 2010]. This 
comprehensive analysis found that VOD was 
reported in up to 62% (with a mean of 13.7%) of 
patients undergoing SCT following myeloablative 
conditioning. Prevalence varied according to the 
conditioning regimen, the type of transplantation, 
and the diagnostic criteria used [Coppell et al. 
2010] (Table 1). Similarly, in an important recent 
retrospective study of 845 patients who received 
an allogeneic SCT over the past 24 years, the 
cumulative incidence of VOD was found to be 
13.8% using Seattle criteria and 8.8% using 
Baltimore criteria [Carreras et al. 2011]. The inci-
dence of VOD in children undergoing SCT also 
varies, ranging from 11% to 20% [Cesaro et al. 
2005; Lee et al. 2010]. VOD ranges from mild, 
reversible disease to severe illness with multiple 
organ failure (MOF) and death [Kumar et al. 
2003]. In the Carreras retrospective study, 
approximately two-thirds of patients had mild or 
moderate VOD and one-third had severe VOD 
according to Seattle criteria; this was closer to 
50% when Baltimore criteria were used [Carreras 
et al. 2011]. In the Coppell analysis, up to 77% of 
all cases of VOD proved severe, with severe dis-
ease in turn associated with a mortality rate in 
excess of 80% [Coppell et al. 2010]. For severe 
VOD, the death rate in a large single-centre study 
(from Seattle) was reported as 98% [McDonald 
et al. 1993]. Many alternative conditions that 
adversely affect the liver after transplantation can 
mimic the signs and symptoms of VOD; diagnosis 
of VOD, especially in its early stages, is therefore a 
clinical challenge [Kumar et al. 2003]. In addition 
to the emergence of MOF, the risk for developing 
severe VOD can also be estimated using the 
Bearman prognostic model, which is based on 
height of bilirubin elevation, percentage weight 
gain, and time from transplant (up to day +16), 
although this model has only been validated for 
certain regimens [including cyclophosophamide 
(CY) plus total body irradiation (TBI), busulfan 
(BU) plus CY, and CY, carmustine plus etopo-
side] [Bearman et al. 1993a].
Pathogenesis of veno-occlusive disease
Sinusoidal endothelial cell and hepatocyte injury, 
usually within zone 3 of the hepatic acinus, trig-
gered by intensive chemotherapy conditioning are 
thought to be pivotal in the development of 
VOD [Coppell et al. 2010; Kumar et al. 2003]. 
Endothelial damage and hepatocellular necrosis 
with subendothelial edema and microthrombosis 
are seen (reviewed in [Richardson and Guinan, 
1999; Carreras, 2000]). Fibrin-related aggregates 
and cellular debris occlude the small pores that 
perforate the endothelial lining, causing obstruc-
tion of the venous outflow. This results in intrahe-
patic portal hypertension, which is responsible for 
the main clinical manifestations of VOD (reviewed 
in [Carreras, 2000]). As a consequence of the 
endothelial cell damage, sinusoidal obstruction is 
often prominent on microscopy, leading to the 
alternative terminology sinusoidal obstruction 
syndrome [Kumar et al. 2003]. Cytokines, such as 
interleukin-1, interleukin-2 and tumor necrosis 
factor α, may be elevated due to tissue injury caused 
by both chemotherapy and allogeneic injury, with 
their procoagulant effects on endothelial cell sur-
faces further contributing to the pathogenesis of 
VOD, with endothelial damage leading to further 
cytokine release and serine protease activation 
(e.g. tissue factor) [Baars et al. 1992; Carreras, 
2000; Holler et al. 1990; Nawroth et al. 1986]. 
Conditioning-related injury may be potentiated 
by agents used for GvHD prophylaxis, for exam-
ple sirolimus (or a combination of sirolimus and 
tacrolimus), because sirolimus may accelerate 
the senescence of hepatic endothelial cells after 
conditioning-related injury [Cutler et al. 2010]. 
Sirolimus may also reduce endothelial growth 
factor levels, hindering the healing process [Cutler 
et al. 2010]. Elevated levels of several markers of 
endothelial injury have been described, including 
a key inhibitor of fibrinolysis, plasminogen activa-
tor inhibitor type-1 (PAI-1), and plasma throm-
bomodulin [Nurnberger et al. 1998; Salat et al. 
1994]. PAI-1 inhibits fibrinolysis, may contribute 
to microthrombosis and can exacerbate subsequent 
Table 1. Variables that can influence incidence of 
veno-occlusive disease.
Incidence (%)
All patients with SCT* 14
Diagnostic criteria*  
 Baltimore 10
 Seattle 17
SCT type*  
 Autologous  9
 Allogeneic 13
Conditioning chemotherapy$  
 Oral BU + CY 42
 Intravenous BU + CY 18
*[Coppell et al. 2010].
$[Lee et al. 2005].
BU, busulfan; CY, cyclophosphamide; SCT, stem-cell 
transplantation; VOD, veno-occlusive disease.
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organ failure [Reilly et al. 1994]; as a result, PAI-1 
has become recognized as both a diagnostic and 
prognostic biomarker for VOD [Lee et al. 2002]. 
PAI-1 production is stimulated by transforming 
growth factor β (TGF-β); TGF-β released from 
activated platelets further contributes to hemo-
static imbalance at the level of the sinusoidal 
endothelial surface in patients with VOD via an 
increase in endothelial cell PAI-1 production 
[Pihusch et al. 2005]. TGF-β has been implicated 
in the pathogenesis of fibrosis [Czaja et al. 1989], 
and elevated levels of TGF-β strongly correlate 
with an increased risk of the disease following 
SCT [Anscher et al. 1993]. Also a reduction in 
hepatic nitric oxide (NO) levels has been shown 
to contribute to the development of VOD via 
disruption in sinusoidal integrity and subsequent 
disturbance of sinusoidal perfusion [DeLeve et al. 
2003]. Conversely, NO has been found to play a 
role in reducing hepatocyte damage and increas-
ing hepatic microcirculation in rats, suggesting a 
potential role for NO in the prevention of ischemia-
reperfusion injuries [Kuroki et al. 2004].
Risk factors for veno-occlusive disease
A number of risk factors, both pre and post SCT, 
can predispose patients to developing VOD. 
Pretransplant risk factors include patient-related 
factors, such as older patient age, female gender, 
pre-existent liver injury (especially cirrhosis) and 
advanced malignancy (reviewed in [Ho et al. 
2008]). Allogeneic SCT is associated with a mark-
edly increased risk of development of VOD com-
pared with autologous SCT (Table 1); this could 
be due to the use of cyclosporin or methotrexate 
for the prophylaxis of GvHD, or may indicate an 
allogeneic immunological element in the devel-
opment of VOD [Carreras, 2000] via cytokine 
dysfunction and inflammation [Richardson and 
Guinan, 1999].
As mentioned above, specific transplant condi-
tioning regimens, including CY followed by TBI 
[McDonald et al. 2003] and BU followed by CY 
[McCune et al. 2007], are associated with the 
development of VOD, although inter-patient 
variability can confound correlations [McCune 
et al. 2007].
In an in vitro study, BU has been shown to deplete 
hepatic glutathione and, at high concentrations, 
induce oxidative stress resulting in BU toxicity 
[DeLeve and Wang, 2000]. Another in vitro study 
revealed that sinusoidal cells are highly sensitive 
to CY metabolites; CY metabolites deplete glu-
tathione by more than 95% and profound deple-
tion of glutathione precedes the onset of toxicity 
[DeLeve, 1996]. Patients undergoing SCT with a 
short interval from administration of gemtuzumab 
ozogamicin, a monoclonal antibody against CD33 
used in the treatment of acute myeloid leukemia 
(AML), have a significantly increased risk of VOD 
development [Wadleigh et al. 2003], possibly due 
to targeting of CD33+ cells in the sinusoids of 
the liver, activation of stellate cells, damage to 
sinusoidal endothelial cells, sinusoidal vasocon-
striction and ischemic hepatocyte necrosis 
[McDonald, 2002]. Prior abdominal irradiation 
has also been found to increase the risk of VOD 
compared with patients with no prior abdominal 
irradiation (13% versus 5%, respectively; p = 
0.009) [Carreras et al. 1998].
Approaches to the prevention of  
veno-occlusive disease
Modification of conditioning and GvHD proph-
ylaxis regimens may reduce the risk of develop-
ing VOD. In patients conditioned with BU plus 
CY, intravenous BU has been found to signifi-
cantly decrease the incidence of VOD after allo-
geneic SCT compared with orally administered 
BU (Table 1) [Lee et al. 2005]. Since CY metab-
olites are implicated as important contributors to 
endothelial injury in VOD, substitution of high-
dose CY in the conditioning regimen may also 
ameliorate VOD risk. Indeed, a recent retrospec-
tive study comparing oral BU plus CY with tar-
geted intravenous BU plus fludarabine (BU/Flu) 
as conditioning therapy in patients with AML 
demonstrated that high-dose BU/Flu was associ-
ated with less early toxicity, including VOD 
[Pidala et al. 2010]. In addition, caution has been 
advised against intensive treatment with gemtu-
zumab ozogamicin, especially within 3 months of 
SCT, to reduce the risk of VOD [McKoy et al. 
2007; Ho et al. 2004]. Gemtuzumab ozogamicin 
(Mylotarg, Wyeth Pharmaceuticals, Philadelphia, 
PA, USA) was withdrawn from the US market in 
2010 following reports of increased incidence of 
VOD in patients with AML in the absence of SCT 
as well as during the early post-transplantation 
period in patients who had been previously treated 
with the agent.
VOD risk may also be reduced by careful con-
sideration of choice of GvHD prophylaxis in 
patients undergoing allogeneic SCT. For exam-
ple, use of ex vivo T-cell depletion as GvHD 
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prophylaxis has been associated with a lower 
risk of VOD [Moscardó et al. 2001]. Conversely, 
if pharmacological GvHD prophylaxis is 
employed, the combination of tacrolimus, 
sirolimus, and methotrexate is associated with 
a higher risk of VOD compared with tacrolimus 
and methotrextate [Cutler et al. 2008]. Further, 
the use of sirolimus as GvHD prophylaxis after 
high-dose BU/CY conditioning appears to fur-
ther escalate the risk of severe VOD [Cutler 
et al. 2008].
Pharmacological prevention
As VOD is associated with aberrant fibrin depo-
sition leading to sinusoidal and/or central vein 
occlusion, antithrombotic or fibrolytic agents 
have been investigated as prophylaxis for VOD. 
In an animal model, antithrombin III has been 
shown to exert anti-inflammatory properties 
[Okada et al. 1999] and potentially reverse pro-
coagulant stress at the level of the endothelium 
[Richardson and Guinan, 2001; Richardson 
et al. 2010b]. However, antithrombin III as 
prophylaxis has not been found to decrease VOD 
incidence [Haussmann et al. 2006]. Separately, a 
recent study in 374 children undergoing SCT 
suggests that prostaglandin E1 may have a pro-
tective effect against the development of VOD 
and may therefore be suitable for prophylaxis, 
although tolerability proved to be an issue [Lee 
et al. 2010]. Similarly, an earlier study found 
that significant toxicity occurred with prosta-
glandin E1 prophylaxis in patients undergoing 
SCT [Bearman et al. 1993b], and its ability to 
prevent severe VOD therefore remains unproven. 
Heparin prophylaxis, including combination 
therapy, has shown some potential to reduce the 
incidence of VOD [Batsis et al. 2006; Forrest 
et al. 2003; Lakshminarayanan et al. 2010]. 
Randomized clinical trials are required to clar-
ify the otherwise mixed data observed to date. 
Ursodiol (ursodeoxycholic acid) as prophylaxis 
following allogeneic SCT has been associated 
with a reduced incidence of VOD [Essell et al. 
1998; Ohashi et al. 2000]. However, a multi-
center randomized trial from the Nordic Bone 
Marrow Transplantation Group comparing 
patients with or without ursodiol treatment prior 
to and after allogeneic SCT did not show any 
benefit in terms of VOD, although improved 
overall survival and reduced hepatic complica-
tions were observed in the ursodiol arm [Ruutu 
et al. 2002].
Management of veno-occlusive disease
Current standard management of VOD focuses 
on best supportive care, which includes avoidance 
of hepatorenal toxic agents, management of fluid 
overload with diuresis, paracentesis for large vol-
ume ascites, ventilator support and hemodialysis 
as clinically indicated [DeLeve et al. 2009]. In 
rare cases, liver transplantation may be considered 
[DeLeve et al. 2009].
There are currently no standard approved phar-
macological agents for the treatment of VOD in 
the USA or the EU. Systemic anticoagulants or 
thrombolytics such as tissue plasminogen acti-
vator (tPA) have been investigated as treatment 
options for established VOD, but they have 
been associated with significant bleeding com-
plications, including fatal events, thus limiting 
their utility and with no survival benefit observed 
(reviewed in [Ho et al. 2008]).
Defibrotide
Defibrotide is a promising candidate for the 
treatment of VOD due to its pleiotropic effects at 
the endothelial surface, and the relatively low 
risk of significant systemic bleeding associated 
with its use [Richardson and Guinan, 1999, 2001]; 
exciting new data on defibrotide are now availa-
ble in this setting.
Mechanisms of action. Defibrotide is a polydis-
perse mixture of porcine-derived single-stranded 
oligonucleotides, which was initially identified as 
an adenosine receptor agonist [Bianchi et al. 
1993]. However, subsequent preclinical studies 
have shown defibrotide to have multiple actions 
in the micro- and macrovasculature, and have 
confirmed defibrotide as an attractive candidate 
agent for the treatment of VOD [Echart et al. 
2009; Falanga et al. 2003].
Studies have revealed that defibrotide confers 
antithrombotic properties by increasing levels of 
the fibrinolytic protein plasmin, through increase 
in tPA, which activates plasminogen to plasmin 
[Falanga et al. 2003], by increasing activity of 
plasmin itself [Echart et al. 2009], and by reduc-
ing PAI-1 levels [Falanga et al. 2003]. In addition, 
defibrotide reduces the amount of a key endothe-
lial cell surface procoagulant tissue factor (TF), 
through blocking TF deposition in the extracel-
lular matrix [Palomo et al. 2011] and stimulating 
release of TF pathway inhibitor [Benimetskaya 
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et al. 2008] as well as other vascular mediators, 
such as NO [Richardson and Guinan, 2001]. 
Thus, defibrotide may limit the organ dysfunction 
and thrombotic microangiopathies associated 
with fibrin deposition [Falanga et al. 2003]. In 
addition, defibrotide has been shown to protect 
endothelial cells against apoptosis induced by 
certain cytotoxic drugs [Eissner et al. 2002] and 
to prevent allogeneic responses of CD8 cells 
against endothelial targets.
Defibrotide has also been shown to confer anti-
inflammatory properties. Preclinical studies have 
found that the proinflammatory p38 mitogen-
activated protein kinase and Akt cell signaling 
pathways are upregulated in endothelial cells 
that have been incubated in sera from patients 
after autologous SCT [Palomo et al. 2011]. 
These signaling pathways were inactivated by 
defibrotide [Palomo et al. 2011]. Moreover, the 
same group observed that elevated levels of 
intercellular adhesion molecule-1 (ICAM-1), 
which are associated with blood vessel inflam-
mation [Lawson and Wolf, 2009], were blocked 
by defibrotide [Palomo et al. 2011]. Previous 
exposure and continuous incubation of cultured 
endothelial cells with defibrotide prevented 
the signs of activation and damage induced by 
sera from patients following autologous SCT, 
indicating that defibrotide has protective anti-
inflammatory and antithrombotic effects in this 
setting [Palomo et al. 2011].
Furthermore, defibrotide may provide a stimulus 
to the sinusoidal endothelium of a damaged liver 
and aid in revascularization. In vitro, defibrotide 
was found to promote endothelial cell prolifera-
tion and angiogenesis, in addition to stimulating 
tubular morphogenesis [Benimetskaya et al. 2008].
Defibrotide may also have a protective effect 
against acute GvHD. Elevated expression of the 
heparanase gene was identified as a risk factor for 
acute GvHD following SCT [Ostrovsky et al. 
2010], and defibrotide has been shown to suppress 
heparanase expression [Mitsiades et al. 2009]. 
Activation of adenosine receptors has been found 
to inhibit T-cell function with the potential for 
prevention and treatment of acute GvHD [Lappas 
et al. 2010; Saldanha-Araujo et al. 2011].
Clinical assessment of defibrotide. Defibrotide 
does not interfere with chemotherapeutics in 
vitro, and it has been shown to reduce resistance 
to chemotherapy in vitro and in animal models, 
although defibrotide has no antitumor properties 
of its own [Mitsiades et al. 2009]. Defibrotide is 
well tolerated and can be administered intrave-
nously, intramuscularly, or orally (reviewed by 
[Palmer and Goa, 1993]).
The first study to evaluate defibrotide for the 
treatment of severe VOD was performed in the 
USA and analyzed 19 patients with severe VOD 
after SCT (defined as bilirubin >2 mg/dl, and two 
or more of the following clinical features: hepato-
megaly and right upper quadrant pain, ascites, or 
>5% weight gain above admission weight), with 
patients treated on a compassionate-use basis 
[Richardson et al. 1998]. Resolution of VOD (<2 
mg/dl bilirubin and improvement in other symp-
toms) was observed in eight patients (42%), six of 
whom survived for longer than 100 days, and no 
significant bleeding was seen. Although this was a 
retrospective study and of limited sample size, the 
encouraging findings prompted a European mul-
ticenter compassionate-use study, which assessed 
defibrotide in 40 patients with VOD post SCT 
(according to either the Baltimore or Seattle cri-
teria) [Chopra et al. 2000]. This study reported a 
complete response (CR) in 22 patients (55%) 
and 17 patients (43%) were still alive after 100 
days [Chopra et al. 2000], again with no signifi-
cant toxicity described. However, the data were 
based on a retrospective review of eligibility and 
outcome forms at individual treating centers. 
Thus, these results must be interpreted with 
some caution.
The encouraging findings of the initial US expe-
rience led to the enrollment of an additional 69 
patients with severe VOD into a larger multi-
institutional study, to provide a total of 88 
patients as part of an emergency use dose escala-
tion protocol. The study reported CR in 36% of 
patients, with a 100-day survival rate of 35% 
[Richardson et al. 2002]. A decrease in PAI-1 
levels during defibrotide treatment was associ-
ated with better outcome. In line with the VOD 
risk factors discussed above, patients who had 
received autologous SCT responded better than 
those who had received allogeneic SCT, and 
improved survival was observed in patients who 
had not previously received BU-based condition-
ing compared with those who had [Richardson 
et al. 2002]. Since this study, several case series 
have reported similar CR rates and improved 
survival with defibrotide in patients with severe 
VOD [Bairey et al. 2002; Palladino et al. 2008; 
Shah et al. 2009].
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In a recent, rigorously conducted, prospective 
phase II, multicenter, randomized, dose-finding 
trial, adult and pediatric patients with severe 
VOD were randomized to receive one of two 
doses of defibrotide (25 mg/kg/day or 40 mg/kg/
day) [Richardson et al. 2010b]. Patients were eli-
gible if they had at least a 30% chance of develop-
ing severe VOD by the Bearman prognostic model 
[Bearman et al. 1993a], or had MOF. Overall, 
46% of 141 evaluable patients achieved CR, and 
the 100-day survival rate was 42% in 149 treated 
patients, with no significant difference in response 
between the two dose regimens. Defibrotide was 
generally well tolerated, with treatment-related 
adverse events reported in only 8% of patients, 
although a trend toward more toxicity was seen 
with the 40 mg/kg/day defibrotide dose compared 
with the 25 mg/kg/day dose, particularly among 
the pediatric patients. Based on these results, 
25 mg/kg/day was the dose selected for further study.
A pivotal phase III, historically-controlled clinical 
trial of defibrotide in patients with severe VOD 
has been recently completed [Richardson et al. 
2009]. The trial comprised 102 patients with 
VOD (according to the Baltimore criteria) within 
21 days of SCT and with MOF (renal and/or lung 
dysfunction) by day 28 post transplant. Patients 
received intravenous defibrotide 6.25 mg/kg every 
6 h (total 25 mg/kg/day) for at least 21 days. Due 
to the life-threatening nature of severe VOD and 
the absence of any other effective treatment as a 
comparator, the placebo arm of this phase III 
study was composed of a matched historical con-
trol (HC). Medical charts at each center were 
reviewed by an independent Medical Review 
Committee (MRC) to provide 32 suitable HC 
patients. The MRC was blinded to outcome data 
from both the defibrotide and HC arms. The pri-
mary endpoint of this trial was CR (bilirubin 
<2 mg/dl and resolution of MOF) by 100 days 
post SCT; the secondary endpoint was 100-day 
mortality. The 100-day CR rate was significantly 
higher in the defibrotide arm compared with the 
HC arm (24% versus 9%, respectively; adjusted 
p = 0.015). There was a substantial decrease in the 
100-day mortality rate with defibrotide compared 
with HC (62% versus 75%, respectively; adjusted 
p = 0.051). A strong correlation was observed 
between CR and survival for both patients receiv-
ing defibrotide (p < 0.0001) and those in the HC 
group (p = 0.0016). Subgroup analysis revealed 
that in patients receiving defibrotide compared 
with those in the HC group, autologous trans-
plantation, age 16 years and younger, and dialysis 
independence were associated with a significantly 
higher CR (p =0.005, 0.04 and p = 0.027, respec-
tively). A similar number of patients in both 
groups experienced hemorrhage: 65% of patients 
receiving defibrotide and 69% of patients in the 
HC group, with treatment discontinued in 18% 
of patients who received defibrotide due to possi-
ble drug-related adverse events. Whilst these 
results are encouraging, it should be noted that 
this phase lll study was not a prospectively rand-
omized study, and matched HCs were used as the 
comparator. Although using a HC methodology 
is not ideal, the absence of any other effective 
treatment as a comparator in patients with severe 
disease limits the options available for ethically 
evaluating the efficacy of defibrotide, and so this 
approach constituted the most reasonable strategy 
in this setting.
A meta-analysis combining results from the 
above phase II and III trials has since been con-
ducted [Richardson et al. 2010c]. Of the total 
133 patients treated with defibrotide 25 mg/kg/
day, 29% achieved a CR by day 100 compared 
with 9% in the HC group (p = 0.0021). The mor-
tality rate at day 100 was 60% in the defibrotide 
cohort versus 75% in the HC cohort (p = 0.0408). 
Hemorrhage and GvHD incidence were lower in 
patients treated with defibrotide compared with 
those in the HC group (61% versus 72%, respec-
tively, for hemorrhage; 6% versus 25% for GvHD). 
The observations of reduced GvHD seen in both 
treatment and prophylactic studies of defibrotide 
are intriguing and imply that endothelial injury is 
also important in the development of acute 
GvHD, so warranting further evaluation [Cooke 
et al. 2008].
Due to the recognition of VOD with MOF as a 
life-threatening condition, defibrotide became 
available in the USA through an investigational 
new drug (IND) treatment protocol in December 
2007. An interim analysis of 104 patients enrolled 
on this protocol from multiple centers found that 
36 patients (35%) achieved a CR at day 100 post 
transplant, and the 100-day overall survival 
was 39% [Richardson et al. 2010a]. From this 
protocol, 69 patients met the eligibility criteria of 
the pivotal phase III trial, and when compared 
with HC counterparts in the phase lll trial, they 
achieved a significantly higher CR rate (p = 
0.0007). Although comparison with matched 
HCs has limitations, as discussed previously, this 
is a promising finding and may reflect the fact 
that this population were marginally less sick in 
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terms of degree of MOF, an observation also 
seen in other studies of defibrotide therapy where 
earlier intervention has been associated with bet-
ter outcome [Corbacioglu et al. 2004; Richardson 
et al. 2010b]; Table 2 summarizes comparable 
data from these larger pivotal studies.
In a recent retrospective analysis of 845 consecu-
tive cases of allogeneic SCT performed in a single 
center during the last 24 years, the mortality rate 
due to VOD was 36% before 1997 compared with 
14% since 1997, the only relevant change in the 
management of these patients being the introduc-
tion of defibrotide [Carreras et al. 2011]. Whilst 
other changes in the management of patients with 
VOD have also been associated with improved 
outcomes, and these include the increasing 
use of reduced-intensity conditioning regimens 
[Ramasamy et al. 2006], use of high-resolution 
human leukocyte antigen typing [Petersdorf, 
2004], improvement of patient support measures, 
plus the increasing use of peripheral blood stem 
cells, this observation was considered compelling 
[Carreras et al. 2011]. Switching administration 
from oral to intravenous BU and using targeted 
dose-adjusted BU also decreases the incidence of 
VOD and may improve outcomes for patients 
with VOD, although the impact of this change on 
survival has been at best very modest in patients 
with established disease [Clopes et al. 2006; 
Kashyap et al. 2002].
Defibrotide as prophylaxis. The promising results 
observed in the treatment trials described above 
provided a good rationale for further investigation 
of defibrotide as prophylaxis against VOD follow-
ing SCT. Although no prospective randomized 
studies in adult SCT have been published to date, 
there have been a number of prospective histori-
cally controlled trials suggesting that defibrotide 
is safe and effective in the setting of VOD preven-
tion. One study compared 52 patients receiving 
defibrotide prophylaxis in addition to heparin 
with a HC group of 52 patients [Chalandon et al. 
2004]. The investigators reported that no patients 
receiving defibrotide and heparin prophylaxis 
developed VOD compared with 19% of patients 
in the HC group (p = 0.001). There was also a 
trend towards improved 100-day survival with 
defibrotide and heparin compared with the HC 
group (p = 0.07). A more recent study evaluated 
58 consecutive patients receiving protocol-directed 
defibrotide prophylaxis without concurrent hep-
arin following allogeneic SCT [Dignan et al. 
2007]. No patients developed VOD (according 
to the Baltimore criteria) and no patients died 
within 100 days of SCT, which was significantly 
better than expected based upon prior incidence 
rates at that center (namely, the Royal Marsden 
Hospital, UK).
The role of defibrotide to prevent VOD in children 
has been recently evaluated in a prospective 
multicenter phase II/III study [Corbacioglu et al. 
2010]. This study randomized 360 children (<18 
years) undergoing myeloablative SCT (69% allo-
geneic, 31% autologous) to either receive prophy-
lactic defibrotide from conditioning to 30 days 
post SCT or no prophylaxis (control group). In the 
intent-to-treat analysis (n = 356) 12% of patients 
in the defibrotide arm versus 20% in the control 
group developed VOD by day 30 after SCT (p = 
0.051). In the per protocol analysis (n = 360) 
VOD incidence was 11% in the defibrotide arm 
versus 20% in the control group (p = 0.023). The 
composite score for morbidity and mortality 
Table 2. Summary of clinical response and overall survival with defibrotide for the treatment of severe hepatic 
veno-occlusive disease.
Clinical response (%) 100-day mortality (%)
Phase II* (N = 149) 46# 42
Phase III$ (N = 102) 24 62
Meta-analysis‡ (N = 133) 29 60
IND protocol§ (N = 104) 35 61
*[Richardson et al. 2010b].
$[Richardson et al. 2009].
‡[Richardson et al. 2010c].
§[Richardson et al. 2010a].
#N = 141.
IND, investigational new drug.
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was significantly lower with defibrotide compared 
with the control (p = 0.034), and renal failure was 
observed in 1% of patients in the defibrotide 
arm versus 6% in the control group (p = 0.017). 
Excluding patients with autologous SCT, the inci-
dence (45% versus 63%; p = 0.004) and severity 
(p = 0.003) of acute GvHD by day 100 was sig-
nificantly reduced in the patients in the defibrot-
ide arm compared with the control arm, suggesting 
that endothelial injury is also important in the 
pathogenesis of GvHD. Results from this pro-
spective randomized trial confirm results from 
previously reported studies showing an advantage 
of defibrotide prophylaxis in children at a high 
risk of developing VOD [Cappelli et al. 2009; 
Corbacioglu et al. 2006; Qureshi et al. 2008; 
Versluys et al. 2004]. Importantly, defibrotide has 
been demonstrated to have favorable effects on 
thrombotic microangiopathy and renal failure 
[Bonomini et al. 1984, 1985; Vangelista et al. 
1986]; preliminary studies in the SCT population 
have been favorable, with a positive effect on renal 
outcome also seen in this large pediatric preven-
tion trial [Corbacioglu et al. 2010].
Future directions
Defibrotide is currently available via an ongoing 
treatment IND study in the USA and elsewhere 
via named patient use programmes, with regula-
tory approval for both treatment and prophylaxis 
of hepatic VOD being actively sought in the EU 
and the USA. Additional studies in prophylaxis 
are planned in adult populations and specific 
high-risk settings.
With improved understanding of the mechanism 
of action of defibrotide and pathogenesis of 
VOD, it may become possible to rationally 
design treatment and preventative strategies for 
VOD based on patient and transplant-specific 
profiles. As an example, subgroup analysis of the 
defibrotide phase III clinical study has already 
identified patients at increased risk of VOD, 
and those most likely to respond to defibrotide 
[Richardson et al. 2009], suggesting that a more 
personalized approach could further improve 
treatment and prevention outcomes. Though 
clinical trials with defibrotide have provided the 
most promising results as effective therapy for 
VOD to date, 100-day mortality from severe 
VOD remains unacceptably high at over 50%. 
Other therapies, such as antithrombin III, 
novel plasminogen activator inhibitors, N-acetyl 
cysteine and other novel antithrombotics may 
warrant further investigation in combination 
with defibrotide [Ho et al. 2008; Ringden et al. 
2000]. If these agents complement defibrotide 
therapy without increasing the risk of bleeding 
or other toxicity, superior outcomes and survival 
may yet be realized.
Importantly, recent observations have found the 
outcome of early intervention with defibrotide to 
be superior to delayed treatment [Richardson 
et al. 2010a]. Elevations of von Willebrand fac-
tor, thrombomodulin, E-selectin, and soluble 
ICAM-1 before and early after allogeneic trans-
plantation may be useful in predicting VOD in 
patients receiving sirolimus [Cutler et al. 2010] 
and could lead to pre-emptive trials based on bio-
markers, leading to improved treatment strategies 
to reverse VOD pathophysiology earlier in spe-
cific high-risk groups [Platzbecker et al. 2009].
Acknowledgements
The authors acknowledge Kate Silverthorne and 
Abigail Marmont for their assistance in writing 
this manuscript, and the administrative assistance 
of Katie Redman and Michelle Maglio of the 
Dana-Farber Cancer Institute.
Funding
Funding for writing and administrative assis-
tance was provided by Gentium S.p.A and the 
Rick Corman Multiple Myeloma Research Fund, 
respectively.
Conflict of interest statement
V.T. Ho, S. Giralt, S. Arai, S. Mineishi, J.H. Antin 
and N. Stavitzski have no conflicts of interest to 
declare. P.G. Richardson is on the advisory board 
for Gentium S.p.A. C. Cutler is consultant for 
Sigma Tau and has equity in Gentium S.p.A. D. 
Niederwieser is a consultant for the speakers 
bureau, Gentium S.p.A. E. Holler has received 
honoraria and research grants from Gentium 
S.p.A. E. Carreras and R. Soiffer have received 
honoraria from Gentium S.p.A.
References
Anscher, M.S., Peters, W.P., Reisenbichler, H., Petros, 
W.P. and Jirtle, R.L. (1993) Transforming growth 
factor beta as a predictor of liver and lung fibrosis after 
autologous bone marrow transplantation for advanced 
breast cancer. N Engl J Med 328: 1592–1598.
Baars, J.W., de Boer, J.P., Wagstaff, J., Roem, D., 
Eerenberg-Belmer, A.J., Nauta, J. et al. (1992) 
 at Universitatsbibliothek on August 23, 2016tah.sagepub.comDownloaded from 
 PG Richardson, VT Ho et al.
http://tah.sagepub.com 261
Interleukin-2 induces activation of coagulation and 
fibrinolysis: resemblance to the changes seen during 
experimental endotoxaemia. Br J Haematol 82: 295–301.
Bairey, O., Kirgner, I., Yakobi, M., Hamdan, A., 
Ben-Ari, Z. and Shaklai, M. (2002) Clinical severe 
hepatic venoocclusive disease during induction 
treatment of acute monoblastic leukemia managed 
with defibrotide. Am J Hematol 69: 281–284.
Batsis, I., Yannaki, E., Kaloyannidis, P., Sakellari, I., 
Smias, C., Georgoulis, I. et al. (2006) Veno-occlusive 
disease prophylaxis with fresh frozen plasma and 
heparin in bone marrow transplantation. Thromb Res 
118: 611–618.
Bearman, S.I. (1995) The syndrome of hepatic 
veno-occlusive disease after marrow transplantation. 
Blood 85: 3005–3020.
Bearman, S.I., Anderson, G.L., Mori, M., Hinds, 
M.S., Shulman, H.M., McDonald, G.B. (1993a) 
Venoocclusive disease of the liver: development of 
a model for predicting fatal outcome after marrow 
transplantation. J Clin Oncol 11: 1729–1736.
Bearman, S.I., Shen, D.D., Hinds, M.S., Hill, 
H.A. and McDonald, G.B. (1993b) A phase I/
II study of prostaglandin E1 for the prevention of 
hepatic venoocclusive disease after bone marrow 
transplantation. Br J Haematol 84: 724–730.
Benimetskaya, L., Wu, S., Voskresenskiy, A.M., 
Echart, C., Zhou, J.F., Shin, J. et al. (2008) 
Angiogenesis alteration by defibrotide: implications 
for its mechanism of action in severe hepatic veno-
occlusive disease. Blood 112: 4343–4352.
Bianchi, G., Barone, D., Lanzarotti, E., Tettamanti, 
R., Porta, R., Moltrasio, D. et al. (1993) Defibrotide, 
a single-stranded polydeoxyribonucleotide acting as 
an adenosine receptor agonist. Eur J Pharmacol  
238: 327–334.
Bonomini, V., Frasca, G.M., Raimondi, C., Liviano, 
D.G. and Vangelista, A. (1985) Effect of a new 
antithrombotic agent (defibrotide) in acute renal 
failure due to thrombotic microangiopathy. Nephron 
40: 195–200.
Bonomini, V., Vangelista, A. and Frasca, G.  
(1984) A new antithrombotic agent in the treatment 
of acute renal failure due to hemolytic-uremic 
syndrome and thrombotic thrombocytopenic 
purpura. Nephron 37: 144.
Cappelli, B., Chiesa, R., Evangelio, C., Biffi, A., 
Roccia, T., Frugnoli, I. et al. (2009) Absence of VOD 
in paediatric thalassaemic HSCT recipients using 
defibrotide prophylaxis and intravenous Busulphan. 
Br J Haematol 147: 554–560.
Carreras, E. (2000) Veno-occlusive disease of the liver 
after hemopoietic cell transplantation. Eur J Haematol 
64: 281–291.
Carreras, E., Bertz, H., Arcese, W., Vernant, J.P., 
Tomas, J.F., Hagglund, H. et al. (1998) Incidence 
and outcome of hepatic veno-occlusive disease after 
blood or marrow transplantation: a prospective cohort 
study of the European Group for Blood and Marrow 
Transplantation. European Group for Blood and 
Marrow Transplantation Chronic Leukemia Working 
Party. Blood 92: 3599–3604.
Carreras, E., Diaz-Beya, M., Rosinol, L., Martinez, 
C., Fernandez-Aviles, F. and Rovira, M. (2011) 
The incidence of veno-occlusive disease following 
allogeneic hematopoietic cell transplantation has 
diminished and the outcome improved over the last 
decade. Biol Blood Marrow Transplant 17: 1713–1720.
Cesaro, S., Pillon, M., Talenti, E., Toffolutti, T., 
Calore, E., Tridello, G. et al. (2005) A prospective 
survey on incidence, risk factors and therapy of 
hepatic veno-occlusive disease in children after 
hematopoietic stem cell transplantation. Haematologica 
90: 1396–1404.
Chalandon, Y., Roosnek, E., Mermillod, B., Newton, 
A., Ozsahin, H., Wacker, P. et al. (2004) Prevention 
of veno-occlusive disease with defibrotide after 
allogeneic stem cell transplantation. Biol Blood Marrow 
Transplant 10: 347–354.
Chopra, R., Eaton, J.D., Grassi, A., Potter, M., 
Shaw, B., Salat, C. et al. (2000) Defibrotide for the 
treatment of hepatic veno-occlusive disease: results of 
the European compassionate-use study. Br J Haematol 
111: 1122–1129.
Clopes, A., Sureda, A., Sierra, J., Queralto, 
J.M., Broto, A., Farre, R. et al. (2006) Absence 
of veno-occlusive disease in a cohort of multiple 
myeloma patients undergoing autologous stem cell 
transplantation with targeted busulfan dosage.  
Eur J Haematol 77: 1–6.
Cooke, K.R., Jannin, A. and Ho, V. (2008) The 
contribution of endothelial activation and injury to 
end-organ toxicity following allogeneic hematopoietic 
stem cell transplantation. Biol Blood Marrow 
Transplant 14: 23–32.
Coppell, J.A., Richardson, P.G., Soiffer, R., 
Martin, P.L., Kernan, N.A., Chen, A. et al. (2010) 
Hepatic veno-occlusive disease following stem cell 
transplantation: incidence, clinical course, and 
outcome. Biol Blood Marrow Transplant 16: 157–168.
Corbacioglu, S., Cesaro, S., Faraci, M., Valteau-
Couanet, D., Gruhn, B., Boelens, J.J. et al. (2010) 
Defibrotide prevents hepatic VOD and reduces 
significantly VOD-associated complications in 
children at high risk: final results of a prospective 
phase II/III multicentre study. Bone Marrow 
Transplant 45 (Suppl. 2): S1.
Corbacioglu, S., Greil, J., Peters, C., Wulffraat, 
N., Laws, H.J., Dilloo, D. et al. (2004) Defibrotide 
 at Universitatsbibliothek on August 23, 2016tah.sagepub.comDownloaded from 
Therapeutic Advances in Hematology 3 (4)
262 http://tah.sagepub.com
in the treatment of children with veno-occlusive 
disease (VOD): a retrospective multicentre study 
demonstrates therapeutic efficacy upon early 
intervention. Bone Marrow Transplant 33: 189–195.
Corbacioglu, S., Honig, M., Lahr, G., Stohr, S., 
Berry, G., Friedrich, W. et al. (2006) Stem cell 
transplantation in children with infantile osteopetrosis 
is associated with a high incidence of VOD, which 
could be prevented with defibrotide. Bone Marrow 
Transplant 38: 547–553.
Cutler, C., Kim, H.T., Ayanian, S., Bradwin, G., 
Revta, C., Aldridge, J. et al. (2010) Prediction of 
veno-occlusive disease using biomarkers of endothelial 
injury. Biol Blood Marrow Transplant 16: 1180–1185.
Cutler, C., Stevenson, K., Kim, H.T., Richardson, 
P., Ho, V.T., Linden, E. et al. (2008) Sirolimus 
is associated with veno-occlusive disease of the 
liver after myeloablative allogeneic stem cell 
transplantation. Blood 112: 4425–4431.
Czaja, M.J., Weiner, F.R., Flanders, K.C., 
Giambrone, M.A., Wind, R., Biempica, L. et 
al. (1989) In vitro and in vivo association of 
transforming growth factor-beta 1 with hepatic 
fibrosis. J Cell Biol 108: 2477–2482.
DeLeve, L.D. (1996) Cellular target of 
cyclophosphamide toxicity in the murine liver: role 
of glutathione and site of metabolic activation. 
Hepatology 24: 830–837.
DeLeve, L.D., Valla, D.C. and Garcia-Tsao, G. 
(2009) Vascular disorders of the liver. Hepatology  
49: 1729–1764.
DeLeve, L.D. and Wang, X. (2000) Role of oxidative 
stress and glutathione in busulfan toxicity in cultured 
murine hepatocytes. Pharmacology 60: 143–154.
DeLeve, L.D., Wang, X., Kanel, G.C., Ito, Y., 
Bethea, N.W., McCuskey, M.K. et al. (2003) 
Decreased hepatic nitric oxide production 
contributes to the development of rat sinusoidal 
obstruction syndrome. Hepatology 38: 900–908.
Dignan, F., Gujral, D., Ethell, M., Evans, S., 
Treleaven, J., Morgan, G. et al. (2007) Prophylactic 
defibrotide in allogeneic stem cell transplantation: 
minimal morbidity and zero mortality from veno-
occlusive disease. Bone Marrow Transplant 40: 79–82.
Echart, C.L., Graziadio, B., Somaini, S., Ferro, 
L.I., Richardson, P.G., Fareed, J. et al. (2009) 
The fibrinolytic mechanism of defibrotide: effect 
of defibrotide on plasmin activity. Blood Coagul 
Fibrinolysis 20: 627–634.
Eissner, G., Multhoff, G., Gerbitz, A., Kirchner, 
S., Bauer, S., Haffner, S. et al. (2002) Fludarabine 
induces apoptosis, activation, and allogenicity in 
human endothelial and epithelial cells: protective 
effect of defibrotide. Blood 100: 334–340.
Essell, J.H., Schroeder, M.T., Harman, G.S., 
Halvorson, R., Lew, V., Callander, N. et al. (1998) 
Ursodiol prophylaxis against hepatic complications 
of allogeneic bone marrow transplantation. A 
randomized, double-blind, placebo-controlled trial. 
Ann Intern Med 128: 975–981.
Falanga, A., Vignoli, A., Marchetti, M. and Barbui, 
T. (2003) Defibrotide reduces procoagulant activity 
and increases fibrinolytic properties of endothelial 
cells. Leukemia 17: 1636–1642.
Forrest, D.L., Thompson, K., Dorcas, V.G., 
Couban, S.H. and Pierce, R. (2003) Low molecular 
weight heparin for the prevention of hepatic veno-
occlusive disease (VOD) after hematopoietic stem cell 
transplantation: a prospective phase II study. Bone 
Marrow Transplant 31: 1143–1149.
Haussmann, U., Fischer, J., Eber, S., Scherer, F., 
Seger, R., Gungor, T. (2006) Hepatic veno-occlusive 
disease in pediatric stem cell transplantation: impact 
of pre-emptive antithrombin III replacement and 
combined antithrombin III/defibrotide therapy. 
Haematologica 91: 795–800.
Ho, V., Momtaz, P., Didas, C., Wadleigh, M. and 
Richardson, P. (2004) Post-transplant hepatic 
veno-occlusive disease: pathogenesis, diagnosis and 
treatment. Rev Clin Exp Hematol 8: E3.
Ho, V.T., Revta, C. and Richardson, P.G. (2008) 
Hepatic veno-occlusive disease after hematopoietic 
stem cell transplantation: update on defibrotide and 
other current investigational therapies. Bone Marrow 
Transplant 41: 229–237.
Holler, E., Kolb, H.J., Moller, A., Kempeni, J., 
Liesenfeld, S., Pechumer, H. et al. (1990) Increased 
serum levels of tumor necrosis factor alpha precede 
major complications of bone marrow transplantation. 
Blood 75: 1011–1016.
Jones, R.J., Lee, K.S., Beschorner, W.E., Vogel, 
V.G., Grochow, L.B., Braine, H.G. et al. (1987) 
Venoocclusive disease of the liver following bone 
marrow transplantation. Transplantation 44: 778–783.
Kashyap, A., Wingard, J., Cagnoni, P., Roy, J., 
Tarantolo, S., Hu, W. et al. (2002) Intravenous versus 
oral busulfan as part of a busulfan/cyclophosphamide 
preparative regimen for allogeneic hematopoietic stem 
cell transplantation: decreased incidence of hepatic 
venoocclusive disease (HVOD), HVOD-related 
mortality, and overall 100-day mortality. Biol Blood 
Marrow Transplant 8: 493–500.
Kumar, S., DeLeve, L.D., Kamath, P.S. and Tefferi, 
A. (2003) Hepatic veno-occlusive disease (sinusoidal 
obstruction syndrome) after hematopoietic stem cell 
transplantation. Mayo Clin Proc 78: 589–598.
Kuroki, I., Miyazaki, T., Mizukami, I., Matsumoto, 
N. and Matsumoto, I. (2004) Effect of sodium 
 at Universitatsbibliothek on August 23, 2016tah.sagepub.comDownloaded from 
 PG Richardson, VT Ho et al.
http://tah.sagepub.com 263
nitroprusside on ischemia-reperfusion injuries of the 
rat liver. Hepatogastroenterology 51: 1404–1407.
Lakshminarayanan, S., Sahdev, I., Goyal, M., 
Vlachos, A., Atlas, M. and Lipton, J.M. (2010) 
Low incidence of hepatic veno-occlusive disease in 
pediatric patients undergoing hematopoietic stem 
cell transplantation attributed to a combination of 
intravenous heparin, oral glutamine, and ursodiol  
at a single transplant institution. Pediatr Transplant  
14: 618–621.
Lappas, C.M., Liu, P.C., Linden, J., Kang, E.M. 
and Malech, H.L. (2010) Adenosine A2A receptor 
activation limits graft-versus-host disease after 
allogenic hematopoietic stem cell transplantation.  
J Leukoc Biol 87: 345–354.
Lawson, C. and Wolf, S. (2009) ICAM-1 signaling in 
endothelial cells. Pharmacol Rep 61: 22–32.
Lee, J.H., Choi, S.J., Lee, J.H., Kim, S.E., Park, 
C.J., Chi, H.S. et al. (2005) Decreased incidence of 
hepatic veno-occlusive disease and fewer hemostatic 
derangements associated with intravenous busulfan 
vs oral busulfan in adults conditioned with busulfan 
+ cyclophosphamide for allogeneic bone marrow 
transplantation. Ann Hematol 84: 321–330.
Lee, J.H., Lee, K.H., Lee, J.H., Kim, S., Seol, 
M., Park, C.J. et al. (2002) Plasminogen activator 
inhibitor-1 is an independent diagnostic marker as 
well as severity predictor of hepatic veno-occlusive 
disease after allogeneic bone marrow transplantation 
in adults conditioned with busulphan and 
cyclophosphamide. Br J Haematol 118: 1087–1094.
Lee, S.H., Yoo, K.H., Sung, K.W., Koo, H.H., 
Kwon, Y.J., Kwon, M.M. et al. (2010) Hepatic 
veno-occlusive disease in children after hematopoietic 
stem cell transplantation: incidence, risk factors, and 
outcome. Bone Marrow Transplant 45: 1287–1293.
McCune, J.S., Batchelder, A., Deeg, H.J., Gooley, T., 
Cole, S., Phillips, B. et al. (2007) Cyclophosphamide 
following targeted oral busulfan as conditioning for 
hematopoietic cell transplantation: pharmacokinetics, 
liver toxicity, and mortality. Biol Blood Marrow 
Transplant 13: 853–862.
McDonald, G.B. (2002) Management of hepatic 
sinusoidal obstruction syndrome following treatment 
with gemtuzumab ozogamicin (Mylotarg). Clin 
Lymphoma 2 (Suppl. 1): S35–S39.
McDonald, G.B., Hinds, M.S., Fisher, L.D., Schoch, 
H.G., Wolford, J.L., Banaji, M. et al. (1993) Veno-
occlusive disease of the liver and multiorgan failure 
after bone marrow transplantation: a cohort study of 
355 patients. Ann Intern Med 118: 255–267.
McDonald, G.B., Sharma, P., Matthews, D.E., 
Shulman, H.M. and Thomas, E.D. (1984) 
Veno-occlusive disease of the liver after bone 
marrow transplantation: diagnosis, incidence, and 
predisposing factors. Hepatology 4: 116–122.
McDonald, G.B., Slattery, J.T., Bouvier, M.E., Ren, 
S., Batchelder, A.L., Kalhorn, T.F. et al. (2003) 
Cyclophosphamide metabolism, liver toxicity, 
and mortality following hematopoietic stem cell 
transplantation. Blood 101: 2043–2048.
McKoy, J.M., Angelotta, C., Bennett, C.L., 
Tallman, M.S., Wadleigh, M., Evens, A.M.  
et al. (2007) Gemtuzumab ozogamicin-associated 
sinusoidal obstructive syndrome (SOS): an  
overview from the research on adverse drug  
events and reports (RADAR) project. Leuk Res  
31: 599–604.
Mitsiades, C.S., Rouleau, C., Echart, C., Menon, 
K., Teicher, B., Distaso, M. et al. (2009) Preclinical 
studies in support of defibrotide for the treatment of 
multiple myeloma and other neoplasias. Clin Cancer 
Res 15: 1210–1221.
Moscardó, F., Sanz, G.F. de la Rubia, J., Jiménez, 
C., Saavedra, S., Regadera, A. et al. (2001) Marked 
reduction in the incidence of hepatic veno-occlusive 
disease after allogeneic hematopoietic stem cell 
transplantation with CD34(+) positive selection. 
Bone Marrow Transplant 27: 983–988.
Nawroth, P.P., Handley, D.A., Esmon, C.T. 
and Stern, D.M. (1986) Interleukin 1 induces 
endothelial cell procoagulant while suppressing 
cell-surface anticoagulant activity. Proc Natl Acad 
Sci U S A 83: 3460–3464.
Nurnberger, W., Michelmann, I., Burdach, S. and 
Gobel, U. (1998) Endothelial dysfunction after 
bone marrow transplantation: increase of soluble 
thrombomodulin and PAI-1 in patients with 
multiple transplant-related complications. Ann 
Hematol 76: 61–65.
Ohashi, K., Tanabe, J., Watanabe, R., Tanaka, 
T., Sakamaki, H., Maruta, A. et al. (2000) The 
Japanese multicenter open randomized trial of 
ursodeoxycholic acid prophylaxis for hepatic  
veno-occlusive disease after stem cell 
transplantation. Am J Hematol 64: 32–38.
Okada, Y., Zuo, X.J., Marchevsky, A.M., 
Nicolaidou, E., Toyoda, M., Matloff, J.M.  
et al. (1999) Antithrombin III treatment improves 
parameters of acute inflammation in a highly 
histoincompatible model of rat lung allograft 
rejection. Transplantation 67: 526–528.
Ostrovsky, O., Shimoni, A., Rand, A., Vlodavsky, 
I. and Nagler, A. (2010) Genetic variations in the 
heparanase gene (HPSE) associate with increased 
risk of GVHD following allogeneic stem cell 
transplantation: effect of discrepancy between 
recipients and donors. Blood 115: 2319–2328.
 at Universitatsbibliothek on August 23, 2016tah.sagepub.comDownloaded from 
Therapeutic Advances in Hematology 3 (4)
264 http://tah.sagepub.com
Palladino, M., Miele, L., Pompili, M., Forgione, A., 
Vellone, V., Vecchio, F.M. et al. (2008) Severe veno-
occlusive disease after autologous peripheral blood 
stem cell transplantation for high-grade non-Hodgkin 
lymphoma: report of a successfully managed case and 
a literature review of veno-occlusive disease.  
Clin Transplant 22: 837–841.
Palmer, K.J. and Goa, K.L. (1993) Defibrotide. A 
review of its pharmacodynamic and pharmacokinetic 
properties, and therapeutic use in vascular disorders. 
Drugs 45: 259–294.
Palomo, M., az-Ricart, M., Rovira, M., Escolar, 
G. and Carreras, E. (2011) Defibrotide prevents 
the activation of macrovascular and microvascular 
endothelia caused by soluble factors released to blood 
by autologous hematopoietic stem cell transplantation. 
Biol Blood Marrow Transplant 14: 497–506.
Petersdorf, E.W. (2004) HLA matching in allogeneic 
stem cell transplantation. Curr Opin Hematol 11: 
386–391.
Pidala, J., Kim, J., Anasetti, C., Kharfan-Dabaja, 
M.A., Nishihori, T., Field, T. et al. (2010) 
Pharmacokinetic targeting of intravenous busulfan 
reduces conditioning regimen related toxicity following 
allogeneic hematopoietic cell transplantation for acute 
myelogenous leukemia. J Hematol Oncol 3: 36.
Pihusch, V., Pihusch, M., Penovici, M., Kolb, H.J., 
Hiller, E. and Pihusch, R. (2005) Transforming 
growth factor beta-1 released from platelets contributes 
to hypercoagulability in veno-occlusive disease 
following hematopoetic stem cell transplantation. 
Thromb Res 116: 233–240.
Platzbecker, U., von Bonin, M., Goekkurt, E., 
Radke, J., Binder, M., Kiani, A. et al. (2009) 
Graft-versus-host disease prophylaxis with 
everolimus and tacrolimus is associated with a high 
incidence of sinusoidal obstruction syndrome and 
microangiopathy: results of the EVTAC trial. Biol 
Blood Marrow Transplant 15: 101–108.
Qureshi, A., Marshall, L. and Lancaster, D. (2008) 
Defibrotide in the prevention and treatment of veno-
occlusive disease in autologous and allogeneic stem 
cell transplantation in children. Pediatr Blood Cancer 
50: 831–832.
Ramasamy, K., Lim, Z.Y., Pagliuca, A., Grundy, R., 
Devereux, S., Ho, A.Y. et al. (2006) Incidence and 
management of hepatic venoocclusive disease in 237 
patients undergoing reduced-intensity conditioning 
(RIC) haematopoietic stem cell transplantation 
(HSCT). Bone Marrow Transplant 38: 823–824.
Reilly, T.M., Mousa, S.A., Seetharam, R. and 
Racanelli, A.L. (1994) Recombinant plasminogen 
activator inhibitor type 1: a review of structural, 
functional, and biological aspects. Blood Coagul 
Fibrinolysis 5: 73–81.
Richardson, P. and Guinan, E. (1999) The pathology, 
diagnosis, and treatment of hepatic veno-occlusive 
disease: current status and novel approaches.  
Br J Haematol 107: 485–493.
Richardson, P. and Guinan, E. (2001) Hepatic 
veno-occlusive disease following hematopoietic stem 
cell transplantation. Acta Haematol 106: 57–68.
Richardson, P., Tomblyn, M., Kernan, N., 
Brochstein, J.A., Mineishi, S., Termuhlen, A.  
et al. (2009) Defibrotide (DF) in the treatment of 
severe hepatic veno-occlusive disease (VOD) with 
multi-organ failure (MOF) following stem cell 
transplantation (SCT): results of a phase 3 study 
utilizing a historical control. Blood 114: abstract 654.
Richardson, P.G., Elias, A.D., Krishnan, A., 
Wheeler, C., Nath, R., Hoppensteadt, D. et al. 
(1998) Treatment of severe veno-occlusive disease 
with defibrotide: compassionate use results in 
response without significant toxicity in a high-risk 
population. Blood 92: 737–744.
Richardson, P.G., Murakami, C., Jin, Z., Warren, 
D., Momtaz, P., Hoppensteadt, D. et al. (2002) 
Multi-institutional use of defibrotide in 88 patients 
after stem cell transplantation with severe veno-
occlusive disease and multisystem organ failure: 
response without significant toxicity in a high-risk 
population and factors predictive of outcome. Blood 
100: 4337–4343.
Richardson, P.G., Smith, A., Arai, S., Grupp, S., 
Kernan, N.A., Adams, R., et al. (2010a). Defibrotide 
(DF) in the treatment of severe hepatic veno-occlusive 
disease (VOD) with multi-organ failure (MOF): 
results of a treatment IND expanded access protocol. 
Blood 116: abstract 906.
Richardson, P.G., Soiffer, R.J., Antin, J.H., Uno, H., 
Jin, Z., Kurtzberg, J. et al. (2010b) Defibrotide for the 
treatment of severe hepatic veno-occlusive disease and 
multiorgan failure after stem cell transplantation: a 
multicenter, randomized, dose-finding trial. Biol Blood 
Marrow Transplant 16: 1005–1017.
Richardson, P.G., Steinbach, G., Kernan, N., 
Guinan, E.C., Chen, A.R., Martin, P.L., et al. 
(2010c) Meta-analysis of defibrotide (DF) in the 
treatment of severe hepatic veno-occlusive disease 
(VOD) with multi-organ failure (MOF) with 
comparison to a historical control (HC). Blood  
116: abstract 3481.
Ringden, O., Remberger, M., Lehmann, S., 
Hentschke, P., Mattsson, J., Klaesson, S. et al. 
(2000) N-acetylcysteine for hepatic veno-occlusive 
disease after allogeneic stem cell transplantation. 
Bone Marrow Transplant 25: 993–996.
Ruutu, T., Eriksson, B., Remes, K., Juvonen, 
E., Volin, L., Remberger, M. et al. (2002) 
Ursodeoxycholic acid for the prevention of hepatic 
 at Universitatsbibliothek on August 23, 2016tah.sagepub.comDownloaded from 
 PG Richardson, VT Ho et al.
http://tah.sagepub.com 265
complications in allogeneic stem cell transplantation. 
Blood 100: 1977–1983.
Salat, C., Holler, E., Reinhardt, B., Kolb, H.J., 
Seeber, B., Ledderose, G. et al. (1994) Parameters of 
the fibrinolytic system in patients undergoing BMT: 
elevation of PAI-1 in veno-occlusive disease. Bone 
Marrow Transplant 14: 747–750.
Saldanha-Araujo, F., Ferreira, F.I., Palma, P.V., 
Araujo, A.G., Queiroz, R.H., Covas, D.T. et al. 
(2011) Mesenchymal stromal cells up-regulate CD39 
and increase adenosine production to suppress 
activated T-lymphocytes. Stem Cell Res 7: 66–74.
Shah, M.S., Jeevangi, N.K., Joshi, A. and Khattry, 
N. (2009) Late-onset hepatic veno-occlusive disease 
post autologous peripheral stem cell transplantation 
successfully treated with oral defibrotide. J Cancer Res 
Ther 5: 312–314.
Vangelista, A., Frasca, G.M., Raimondi, C., 
Liviano-D'Arcangelo, G. and Bonomini, V. (1986) 
Effects of defibrotide in acute renal failure due to 
thrombotic microangiopathy. Haemostasis 16 
(Suppl. 1): 51–54.
Versluys, B., Bhattacharaya, R., Steward, C., 
Cornish, J., Oakhill, A. and Goulden, N.  
(2004) Prophylaxis with defibrotide prevents  
veno-occlusive disease in stem cell transplantation 
after gemtuzumab ozogamicin exposure. Blood  
103: 1968.
Wadleigh, M., Richardson, P.G., Zahrieh, D., 
Lee, S.J., Cutler, C., Ho, V. et al. (2003) Prior 
gemtuzumab ozogamicin exposure significantly 
increases the risk of veno-occlusive disease in 
patients who undergo myeloablative allogeneic  
stem cell transplantation. Blood 102: 1578–1582.
Visit SAGE journals online 
http://tah.sagepub.com
SAGE journals
 at Universitatsbibliothek on August 23, 2016tah.sagepub.comDownloaded from 
